Saxenda Geriatric (65+) Caregiver Administration Guidance

Does the Saxenda dose change for adults 65 and older?

Saxenda is liraglutide 3 mg, a GLP-1 receptor agonist injected once daily for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition, alongside a reduced-calorie diet and more physical activity [1]. The adult schedule is one table with no age-based step: 0.6 mg daily for week 1, then 1.2 mg, 1.8 mg, 2.4 mg, and 3 mg daily from week 5 onward [1]. Lower doses are for titration only, and the label says to discontinue Saxenda if the 3 mg dose is not tolerated [1]. A published pharmacokinetic review of liraglutide in type 2 diabetes found drug exposure largely independent of age, race and ethnicity [2].

Two label instructions matter more in a 65-plus household than the numbers in the table:

• If a dose increase is not tolerated during escalation, the label says to consider delaying that escalation by approximately one additional week [1].
• The label evaluates adults 16 weeks after starting and says to discontinue Saxenda if baseline body weight has fallen by less than 4%, since clinically meaningful loss is then unlikely [1].

Saxenda should not be combined with any other liraglutide-containing product or with any other GLP-1 receptor agonist [1].

What does the label say about giving the injection?

The label directs training on proper injection technique before the first dose and refers to the accompanying Instructions for Use for complete administration instructions [1]. Before each injection, the solution is inspected and used only if it is clear, colorless and free of particles [1].

Saxenda goes under the skin in the abdomen, thigh or upper arm, once daily at any time of day, without regard to meals, and no dose adjustment is needed if the injection site or timing changes [1]. Injection sites are rotated within the same region to reduce the risk of cutaneous amyloidosis [3].

What should a caregiver watch for after a dose?

Stomach and bowel effects. In five placebo-controlled adult trials (3,384 people on Saxenda, 1,941 on placebo, treatment up to 56 weeks), nausea occurred in 39.3% vs 13.8%, diarrhea in 20.9% vs 9.9%, constipation in 19.4% vs 8.5% and vomiting in 15.7% vs 3.9% [1]. Nausea declined as treatment continued [1]. Treatment was stopped for adverse reactions in 9.8% vs 4.3%, most often for nausea (2.9% vs 0.2%), vomiting (1.7% vs less than 0.1%) or diarrhea (1.4% vs 0%) [1].

Dehydration and kidney function. Vomiting or diarrhea can lead to volume depletion. The label warns about acute kidney injury due to volume depletion and instructs monitoring renal function in patients who report reactions that could lead to volume depletion [1].

Heart rate. Resting heart rate rose by a mean of 2 to 3 bpm on Saxenda compared with placebo. A rise of more than 10 bpm at two consecutive visits occurred in 34% vs 19%, and at least one resting rate above 100 bpm was recorded in 6% vs 4% [1]. The label instructs monitoring heart rate at regular intervals [1].

Low blood sugar when diabetes drugs are also used. In adults with type 2 diabetes taking a sulfonylurea, glucose below 54 mg/dL occurred in 28.2% on Saxenda vs 12.7% on placebo, with sulfonylurea doses reduced 50% at the start of that trial [1]. The label states the hypoglycemia risk may be lowered by reducing the dose of insulin or the insulin secretagogue [1].

What if a dose is missed?

The label says to resume the once-daily regimen with the next scheduled dose and not to take an extra dose or increase the dose to make up for the missed one [1]. If more than 3 days have passed since the last dose, the label says to reinitiate Saxenda at 0.6 mg daily and follow the escalation schedule again, to reduce gastrointestinal reactions associated with restarting [1].

Which other medicines need attention in a 65-plus regimen?

Saxenda delays gastric emptying and therefore has the potential to affect absorption of oral medicines. In clinical pharmacology trials liraglutide did not affect the absorption of the tested oral medicines to a clinically relevant degree, but the label still says to monitor for potential consequences of delayed absorption [1].

What serious problems does the label list?

• Thyroid C-cell tumors. The boxed warning states that liraglutide caused dose- and duration-dependent thyroid C-cell tumors in rats and mice, and that human relevance is unknown. Saxenda is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2, and the label names a mass in the neck, difficulty swallowing, shortness of breath and persistent hoarseness as symptoms of thyroid tumors [1].
• Acute pancreatitis. The label describes persistent or severe abdominal pain, sometimes radiating to the back and sometimes with nausea or vomiting, and says to discontinue Saxenda if pancreatitis is suspected [1].
• Gallbladder disease. Cholelithiasis was reported in 2.2% vs 0.8% and cholecystitis in 0.8% vs 0.4% in adult trials; the label says that if cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated [1].
• Serious allergic reactions. Anaphylaxis and angioedema have been reported after marketing. Serious hypersensitivity to liraglutide or an excipient is a contraindication, and the label says to discontinue Saxenda and other suspect medicines if such a reaction occurs [1].
• Sedation and surgery. Pulmonary aspiration has been reported in patients on GLP-1 receptor agonists during general anesthesia or deep sedation, and the label instructs patients to tell healthcare providers about planned surgeries or procedures [1].
• Mood. FDA asked on 13 January 2026 that the suicidal behavior and ideation warning be removed from Saxenda, Wegovy and Zepbound after its review found no increased risk, and the current Saxenda label no longer contains it [4][1].

Does weight loss differ in adults over 65?

The main Saxenda weight-management trial enrolled 3,731 adults without type 2 diabetes (BMI 30 or higher, or 27 or higher with treated or untreated dyslipidemia or hypertension). At 56 weeks, mean loss was 8.4 kg with liraglutide 3 mg vs 2.8 kg with placebo, a difference of 5.6 kg [5]. In SCALE Maintenance, 422 adults who had already lost at least 5% of body weight on a low-calorie diet lost a further 6.2% from randomization with liraglutide vs 0.2% with placebo at week 56 [6].

Those were not geriatric trials. Mean age in the adult Saxenda safety database was 47 years [1]. A 2016 review of liraglutide 3 mg noted limited data in the geriatric population [7], and a 2024 review of obesity drug treatment in older adults concluded that concise guidelines for this age group are not yet available and that trials looking at geriatric endpoints, including muscle mass preservation and bone quality, are still needed [8]. The 4% weight-loss checkpoint at 16 weeks remains the label's own test of whether treatment is working [1].